

CHANGE OF COMPANY SECRETARY

New York, USA, and Melbourne, Australia; 29 August 2014: Mesoblast Limited announced today that Mr Charlie Harrison has been appointed as Company Secretary of Mesoblast Limited, effective 1 September 2014. He replaces Ms Jenni Pilcher who resigned as Company Secretary of Mesoblast Limited effective 31 August 2014.

Mr Harrison joined Mesoblast as legal counsel in 2013. Previously he was a senior associate at the international law firm Allens, working in their Hong Kong and Melbourne offices for nine years as a corporate lawyer.

Mr Harrison is the person nominated under Listing Rule 12.6 for communication with the Australian Securities Exchange (ASX) with regards to Listing Rule matters.

Mesoblast Limited

Mesoblast Limited (ASX: MSB; USOTC: MBLTY) is a world leader in the development of biologic products for the broad field of regenerative medicine. The Company's proprietary adult stem cell technologies include its highly purified, immunoselected Stro-1/Stro-3 positive Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Mesoblast's protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1). Mesoblast's allogeneic or 'off-the-shelf' cell-based products are targeting substantial market areas of unmet medical need, including cardiac and metabolic diseases, inflammatory/immune-mediated conditions, oncology, and orthopedic diseases. Lead products are MSC-100-IV for steroid refractory acute Graft Versus Host Disease, MPC-06-ID for chronic discogenic lower back pain and MPC-150-IM for congestive heart failure. www.mesoblast.com

For further information, please contact:

Julie Meldrum
Global Head of Corporate Communications
Mesoblast Limited
T: +61 (0) 3 9639 6036
E: julie.meldrum@mesoblast.com